UK CF Medical Association Statement on Alyftrek
The CFMA welcomes the recent MHRA approval for the new triple CFTR modulator therapy, Alyftrek. This new medicine may offer an important alternative for some people with CF who are already treated with Kaftrio, with data from the clinical trials showing that it is comparable to Kaftrio at improving lung function. Alyftrek may also be an option for a small number of people who are not eligible for current therapies or have not been able to tolerate them, but current clinical trial data hasn’t revealed the specifics of this. While improvements to therapies is good news, ongoing challenges exist for people with the condition and CF clinical teams will continue to work to achieve excellent health outcomes and quality of life for all. CF remains a condition without a cure and we hope that new therapies will become available for people with CF in the future, particularly for those who do not respond to existing therapies.